Autopsy report · NCT06630247

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

“Company Decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 7 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Exelixis

Sponsor type

Industry

Conditions

Solid Cancers; Solid Tumor Cancer; Solid Tumor Malignancy; Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer); Metastatic Solid Tumor; Locally Advanced Solid Tumor

Interventions

XL495; ADC cytotoxic agents

Participants

9

Sites

10

Countries

United States

Trials that died the same way

• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (97% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (92% match in meaning)
• A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)
  “Corporate decision” (90% match in meaning)
• Postsurgical Analgesia After Hernia Repair
  “Business Decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.